91 related articles for article (PubMed ID: 17337383)
1. [Utility of MRI contrast agents for diagnosis and treatment follow-up in cancer].
Siauve N; Clément O
Bull Cancer; 2007 Feb; 94(2):139-46. PubMed ID: 17337383
[TBL] [Abstract][Full Text] [Related]
2. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
Low RN
Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
[TBL] [Abstract][Full Text] [Related]
3. Cellular magnetic resonance imaging using superparamagnetic anionic iron oxide nanoparticles: applications to in vivo trafficking of lymphocytes and cell-based anticancer therapy.
Smirnov P
Methods Mol Biol; 2009; 512():333-53. PubMed ID: 19347287
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry.
Vincensini D; Dedieu V; Eliat PA; Vincent C; Bailly C; de Certaines J; Joffre F
Magn Reson Imaging; 2007 Apr; 25(3):293-302. PubMed ID: 17371717
[TBL] [Abstract][Full Text] [Related]
5. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
6. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
7. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R
Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment.
Cuenod CA; Fournier L; Balvay D; Guinebretière JM
Abdom Imaging; 2006; 31(2):188-93. PubMed ID: 16447089
[TBL] [Abstract][Full Text] [Related]
9. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications.
Essig M; Weber MA; von Tengg-Kobligk H; Knopp MV; Yuh WT; Giesel FL
Top Magn Reson Imaging; 2006 Apr; 17(2):89-106. PubMed ID: 17198225
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
Medved M; Karczmar G; Yang C; Dignam J; Gajewski TF; Kindler H; Vokes E; MacEneany P; Mitchell MT; Stadler WM
J Magn Reson Imaging; 2004 Jul; 20(1):122-8. PubMed ID: 15221817
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
Hylton N
J Clin Oncol; 2006 Jul; 24(20):3293-8. PubMed ID: 16829653
[TBL] [Abstract][Full Text] [Related]
13. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI.
Cantwell CP; Setty BN; Holalkere N; Sahani DV; Fischman AJ; Blake MA
J Comput Assist Tomogr; 2008; 32(5):738-44. PubMed ID: 18830103
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer.
Turnbull LW
NMR Biomed; 2009 Jan; 22(1):28-39. PubMed ID: 18654999
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium-enhanced imaging of liver tumors and manifestations of hepatitis: pharmacodynamic and technical considerations.
Sharma P; Kitajima HD; Kalb B; Martin DR
Top Magn Reson Imaging; 2009 Apr; 20(2):71-8. PubMed ID: 20010061
[TBL] [Abstract][Full Text] [Related]
16. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
Rosen MA; Schnall MD
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
[TBL] [Abstract][Full Text] [Related]
19. Molecular MR imaging and MR-guided ultrasound therapies in cancer.
Grenier N; Quesson B; de Senneville BD; Trillaud H; Couillaud F; Moonen C
JBR-BTR; 2009; 92(1):8-12. PubMed ID: 19358479
[TBL] [Abstract][Full Text] [Related]
20. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
